Myeloperoxidase and elastic-collagen frame in the formation of unstable atherosclerotic plaque in human



Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Background: Currently, there is a number of evidence indicating the possible involvement of myeloperoxidase in the pathogenesis of atherosclerosis. However, its role in the formation of unstable atherosclerotic lesions in human and its effect on the elastic-collagen frame in the vascular wall remain poorly studied.

AIM: The purpose of the work is to conduct a comparative immunohistochemical analysis of the content of myeloperoxidase, smooth muscle cells, as well as elastic and collagen fibers in various types of atherosclerotic lesions in human.

Materials and methods: Histological and immunohistochemical examination was carried out on autopsy material (21 cases) obtained from persons who died from acute cardiovascular failure of atherosclerotic etiology. The segments of the aorta (from the arch, thoracic and abdominal regions), coronary arteries and basilaris arteries were examined - a total of 50 tissue samples. Expression of myeloperoxidase in various types of atherosclerotic lesions of the vascular wall was detected by a highly sensitive two-step avidin-biotin method.

Results:  Intracellular localization of myeloperoxidase was found in the intima of unstable atherosclerotic plaques, which increases as this type of atherosclerotic lesion progresses. At the same time, unstable plaques show a sharp decrease in the number of smooth muscle cells and destruction of the elastic-collagen frame with the destruction of elastic and collagen fibers and the rupture of the plaque cap.

Conclusion: It is hypothesized that the production of myeloperoxidase by mononuclear cells can have a negative effect on smooth muscle cells, promoting their apoptosis, followed by inhibition of the synthesis of elastic and collagen fibers in the vascular wall. Established facts can be considered as a mechanism leading to destabilization of atherosclerotic damage in human.

Sobre autores

Peter Pigarevsky

Institute of Experimental Medicine, St. Petersburg

Email: pigarevsky@mail.ru
ORCID ID: 0000-0002-5906-6771
Código SPIN: 8636-4271

Dr. Sci. (Biol.),  Head of the Laboratory of Atherosclerosis named after N.N. Anichkov, Department of Biochemistry

Rússia, adress:12 Akad. Pavlov street, 197376, Saint Petersburg, Russia

Svetlana Maltseva

Institute of Experimental Medicine, St. Petersburg

Email: moon25@rambler.ru
ORCID ID: 0000-0001-7680-8485
Código SPIN: 8367-9096

Cand. Sci.  (Biology), Researcher Associate department of biochemistry

Rússia, adress:12 Akad. Pavlov street, 197376, Saint Petersburg, Russia

Vlada Snegova

Institute of Experimental Medicine, St. Petersburg

Email: biolaber@inbox.ru
ORCID ID: 0000-0002-9925-2886
Código SPIN: 8088-4446

Cand. Sci.  (Biology), Researcher Associate department of biochemistry

Rússia, adress:12 Akad. Pavlov street, 197376, Saint Petersburg, Russia

Natalya Davydova

Institute of Experimental Medicine, St. Petersburg

Email: tatashaspb@yandex.ru
ORCID ID: 0000-0002-4522-6789
Código SPIN: 4761-3575

Cand. Sci.  (Medicine), Researcher Associate department of biochemistry

Rússia, adress:12 Akad. Pavlov street, 197376, Saint Petersburg, Russia

Olga Yakovleva

Institute of Experimental Medicine, St. Petersburg

Autor responsável pela correspondência
Email: emalonett@yandex.ru
ORCID ID: 0000-0002-6248-9468
Código SPIN: 4963-5064

Researcher Associate department of biochemistry

Rússia, adress:12 Akad. Pavlov street, 197376, Saint Petersburg, Russia

Bibliografia

  1. Arnhold J. The dual role of myeloperoxidase in immune response. Int J Mol Sci. 2020;21(21):8057. doi: 103390/ijms21218057
  2. Aratani Y. Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys. 2018;640:47-52. doi: 10.1016/j.abb.2018.01.004
  3. Frangie C, Daher J. Role of myeloperoxidase in inflammation and atherosclerosis (Review). Biomed Rep. 2022;16(6):53. doi: 10.3892/br.2022.1536
  4. Teng N, Maghzal GJ, Talib J, Rashid I, Lau AK, Stocker R. The role of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Redox Rep. 2017;22(2):51-73. doi: 10.1080/13510002.2016.1256119
  5. Vanhamme L, Zouaoui Boudjeltia K, Van Antwerpen P, Delporte C. The other myeloperoxidase: Emerging functions. Arch Biochem Biophys. 2018;649:1-14. doi: 10.1016/j.abb.2018.03.037
  6. Nussbaum C, Klinke A, Adam M, Baldus S, Sperandio M. Myeloperoxidase: A leukocyte-derived protagonist of inflammation and cardiovascular disease. Antoxid Redox Signal. 2013;18(6):692-713. doi: 10.1089/ars.2012.4783
  7. Wang Y, Rosen H, Madtes DK, Shao B, Martin TR, Heinecke JW et al. Myeloperoxidase inactivates TIMP-1 by oxidizing its N-terminal cysteine residue: An oxidative mechanism for regulating proteolysis during inflammation. J Biol Chem. 2007;282(44):1826-1834. doi: 10.1074/jbc.M704894200
  8. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage
  9. colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158(3):879-891. doi: 10.1016/S0002-9440(10)64036-9
  10. Nadel J, Jabbour A, Stocker R. Arterial myeloperoxidase in the detection and treatment of vulnerable atherosclerotic plaque: a new dawn for an old light. Cardiovasc Res. 2023;119(1):112-120. doi: 10.1093/cvr/cvac081
  11. Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: A useful biomarker for cardiovascular disease risk stratification? Clin Chem. 2009;55(8):1462-1470. doi: 10.1373/clinchem.2009.126029
  12. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J. 2001;142(2):336-339. doi: 10.1067/mhj.2001.116769
  13. Tong W, Hui H, Shang W, Zhang Y, Tian F, Ma Q et al. Highly sensitive magnetic particle imaging of vulnerable atherosclerotic plaque with active myeloperoxidase-tergeted nanoparticles. Theranostics. 2021;11(2):506-521. doi: 10.7150/thno.49812
  14. Kosowski M, Basiak M, Hachula M, Okopien B. Plasma concentrations of new biochemical markers of atherosclerosis in patients with dyslipidemia – A pilot study. Medicina (Kaunas). 2022;58(6):717. doi: 10.3390/medicina58060717
  15. Chaikijurajai T, Tang W. Myeloperoxidase: a potential therapeutic target for coronary artery disease. Expert Opin Ther Targets. 2020;24(7):695-705. doi: 10.1080/14728222.2020.1762177

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Pigarevsky P.V., Maltseva S.V., Snegova V.A., Davydova N.G., Yakovleva O.G.,